Erelzi vs. Eticovo

• Are Eticovo and Erelzi the Same Thing?
• What Are Possible Side Effects of Erelzi?
• What Are Possible Side Effects of Eticovo?
• What is Erelzi?
• What is Eticovo?
• What Drugs Interact with Erelzi?
• What Drugs Interact with Eticovo?
• How Should Erelzi Be Taken?
• How Should Eticovo Be Taken?

Erelzi (etanercept-szzs) injection and Eticovo (etanercept-ykro) are tumor necrosis factor (TNF) blockers used to treat certain autoimmune disorders such as rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO).

Erelzi and Eticovo are biosimilar to Enbrel (etanercept).

Side effects of Erelzi and Eticovo that are similar include infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza), injection site reactions (redness, itching, pain, swelling, bleeding, bruising), diarrhea, rash, hives, and fever.

Both Erelzi and Eticovo may interact with live vaccines, anakinra, abatacept, and cyclophosphamide.

Common side effects of Erelzi include:

• infections,
• injection site reactions (redness, itching, pain, swelling, bleeding, bruising),
• diarrhea,
• rash,
• hives, and
• fever.

Common side effects of Eticovo include:

• infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza),
• injection site reactions,
• diarrhea,
• rash,
• itching,
• fever, and
• hives

Erelzi (etanercept-szzs) injection, for subcutaneous use is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO).

Eticovo (etanercept-ykro) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years or older. Eticovo is biosimilar to Enbrel (etanercept).

Erelzi may interact with live vaccines, anakinra, abatacept, and cyclophosphamide. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Erelzi. It is unknown if it would affects a fetus. Erelzi passes into breast milk but it is unknown if it would affect a nursing baby. Consult your doctor before breastfeeding.

Eticovo may interact with "live vaccines," anakinra, abatacept, and cyclophosphamide, and sulfasalazine. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Eticovo; it is unknown how it would affect a fetus. Eticovo passes into breast milk in low levels. Consult your doctor before breastfeeding.

The dose of Erelzi to treat adult RA and PsA is 50 mg once weekly with or without methotrexate; the dose of Erelzi to treat AS is 50 mg once weekly; the dose of Erelzi to treat adult PsO is 50 mg twice weekly for 3 months, followed by 50 mg once weekly; and the dose of Erelzi to treat JIA (patients who weigh >63 kg) is 0.8 mg/kg weekly, with a maximum of 50 mg per week.

The dose of Eticovo to treat adult rheumatoid arthritis and psoriatic arthritis is 50 mg once weekly with or without methotrexate (MTX). The dose of Eticovo to treat ankylosing spondylitis is 50 mg once weekly. The dose of Eticovo to treat adult plaque psoriasis is 50 mg twice weekly for 3 months, followed by 50 mg once weekly. The dose of Eticovo to treat pediatric plaque psoriasis or plaque psoriasis (patients who weigh 63 kg or more) is 50 mg once weekly.